Curative treatment in acute myeloid leukemia (AML) depends on successful induction
therapy to achieve a complete remission (CR), and subsequent post‐remission therapy to …

Abstract Machine learning (ML) is rapidly emerging in several fields of cancer research. ML
algorithms can deal with vast amounts of medical data and provide a better understanding of …

Dear Editor, Patients with high-risk AML ineligible for allogeneic hematopoietic stem cell
transplantation (allo-SCT) have poor outcomes and low likelihood of cure 1. Maintenance …

Patients with relapsed/refractory acute myeloid leukemia (R/R AML) often show resistance to
chemotherapy and have dismal outcomes. Therefore, it is urgent to develop new treatment …

Allogeneic haematopoietic stem cell transplantation (HSCT) is a potentially curative
treatment for some patients with acute myeloid leukaemia (AML) who are refractory to …

Considerable progress has been made in the treatment of acute myeloid leukemia (AML).
However, current therapeutic results are still unsatisfactory in untreated high-risk patients …

Recent advances in therapeutics coupled with steady improvements in supportive care for
patients with acute myeloid leukemia (AML) have led to improved outcomes. Despite these …

Acute myeloid leukemia (AML) is an aggressive hematological tumor caused by the
malignant transformation of myeloid progenitor cells. Although intensive chemotherapy …

The pivotal RATIFY study demonstrated midostaurin (50 mg twice daily) with standard
chemotherapy significantly reduced mortality in adult patients (< 60 years) with newly …

Background Acute myeloid leukemia (AML) is the most common hematological malignancy
in adult patients. Ferroptosis-related signatures have been shown to act as regulators of the …